Skip to main content
SpringerLink
Log in

The Immunobiology of Ovarian Carcinoma

  • Chapter
Gynecologic Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 10))

Abstract

Knowledge of the immunobiology of ovarian carcinoma may aid in the detection, staging, and treatment of this malignancy. In all probability, the immune response to ovarian carcinoma is affected by many of the same factors which influence immunological resistance to tumors that arise from other organs. In addition, several facets of ovarian tumor immunology almost certainly reflect the unique biology of epithelial neoplasms that develop at this particular site.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Black PH: Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 32:75–199, 1980.

    PubMed  CAS  Google Scholar 

  2. Ohanian SH, Schlager SI: Humoral immune killing of nucleated cells: Mechanisms of complement-mediated attack and target cell defense. CRC Critical Reviews in Immunology 1:165–209, 1981.

    PubMed  CAS  Google Scholar 

  3. Ritz J, Pesando JM, Notis-McConarty J, Schlossman SF: Modulation of human acute lymphoblastic leukemia induced by monoclonal antibody in vitro. J Immunol 125:1506, 1980.

    PubMed  CAS  Google Scholar 

  4. Stackpole CW, Jacobson JB: Antigenic modulation. Handbook of Cancer Immunology 2:55–159, 1978.

    CAS  Google Scholar 

  5. Benacerraf B, Unanue FR: Textbook of Immunology. Baltimore: Williams and Wilkens, 1979.

    Google Scholar 

  6. Reinherz EL, Schlossman SF: Regulation of the immune response-inducer and suppressor T-lymphocyte subsets in human beings. New England J Med 303:370–373, 1980.

    CAS  Google Scholar 

  7. Henney CS: Mechanisms of tumor cell destruction. In: Mechanisms of tumor immunity. Green I, Cohen S, McCluskey RT (eds). New York: John Wiley and Sons, 1977, pp 55–86.

    Google Scholar 

  8. Nathan CF, Murray HW, Cohn ZA: The macrophage as an effector cell. New Engl J Med 303:622–626, 1980.

    PubMed  CAS  Google Scholar 

  9. Herberman RB, Ortaldo JR: Natural killer cells: Their role in defenses against disease. Science 214:24–30, 1981.

    PubMed  CAS  Google Scholar 

  10. Bast RC Jr, Rapp HJ: The immunology of animal tumors. In: Immunological Diseases. Samter M (ed). Boston: Little Brown and Company, 1978 (3rd ed), pp 359–388.

    Google Scholar 

  11. Broder S, Waldmann TA: The suppressor cell network in cancer. New Engl J Med 299:1281–1284; 1335–1344, 1978.

    PubMed  CAS  Google Scholar 

  12. Perry LL, Greene MI: T cell subset interactions in the regulation of syngeneic tumor immunity. Fed Proc 40:39–44, 1981.

    PubMed  CAS  Google Scholar 

  13. Bast RC Jr: Effects of cancers and their treatment on host immunity. In: Cancer Medicine. Holland JF, Frei E III (eds). Philadelphia: Lea and Febiger, 1982 (2nd ed), pp 1134–1174.

    Google Scholar 

  14. Knapp RC, Berkowitz RS, Leavitt T Jr: Natural history and detection of ovarian cancer. In: Gynecologic Oncology. Buchsbaum HJ (ed). Maryland: Harper and Row, 1980, Vol. 4, pp 1–14.

    Google Scholar 

  15. Van Nagell JR, Donaldson ES, Gay EC, Sharkey RM, Rayburn P, Goldenberg DM: Carcinoembryonic antigen in ovarian epithelial cystadenocarcinomas. The prognostic value of tumor and serial plasma determinations. Cancer 41:2335–2340, 1978.

    PubMed  Google Scholar 

  16. Feldman GB, Knapp RC, Order SE, Hellman S: The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 32:1663–1666, 1972.

    PubMed  CAS  Google Scholar 

  17. Parker LM, Griffiths CT, Yankee RA, Canellos GP, Gelman R, Knapp RC, Richman CM, Tobias JS, Weiner RS, Frei E III: Combination chemotherapy with adriamycin-cyclophos-phamide for advanced ovarian carcinoma. Cancer 46:669–674, 1980.

    PubMed  CAS  Google Scholar 

  18. Longo DL, Young RC: The natural history and treatment of ovarian cancer. Ann Rev Med 32:475–490, 1981.

    PubMed  CAS  Google Scholar 

  19. Bast RC Jr, Zbar B, Borsos T, Rapp IIJ: BCG and cancer. New Engl J Med 290:1413–1420; 1458–1469, 1974.

    PubMed  Google Scholar 

  20. Bast RC Jr, Bast BS, Rapp HJ: Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. Ann New York Acad Sci 277:60–93, 1976.

    CAS  Google Scholar 

  21. Oettgen HF, Hellstrom KE: Tumor immunology. In: Cancer Medicine. Holland JF, Frei E III (eds). Boston: Lea and Febiger, 1982 (2nd ed), pp 1029–1067.

    Google Scholar 

  22. Zamcheck W, Kupchik HZ: Summary of clinical use and limitations of the carcinoembryonic antigen assay and some methodological considerations. In: Manual of Clinical Immunology. Rose NR, Friedman H (eds). Washington D.C.: American Society for Microbiology, 1980 (2nd ed), pp 919–935.

    Google Scholar 

  23. Stall KE, Martin EW: Plasma carcinoembryonic antigen levels in ovarian cancer patients: A chart review and survey of published data. J Reprod Med 26:75–79, 1981.

    Google Scholar 

  24. Donaldson ES, Van Nagell JR, Pursell S, Gay EC, Meeker WR, Kashmiri R, Van de Voorde J: Multiple biochemical markers in patients with gynecologic malignancies. Cancer 45:948–853, 1980.

    PubMed  CAS  Google Scholar 

  25. Khoo SK, Whitaker S, Jones I, Mackay E: Predictive value of serial carcinoembryonic antigen levels in long-term follow-up of ovarian cancer. Cancer 43:2471–2478, 1979.

    PubMed  CAS  Google Scholar 

  26. Marchand A, Ferroglio CM, Pascal R, Richart RM, Bennett S: Carcinoembryonic antigens in human ovarian neoplasms. Cancer Res 35:3807–3810, 1975.

    PubMed  CAS  Google Scholar 

  27. Khoo SK, Whitaker S, Jones ISC, Mackay EV: Carcinoembryonic antigen in patients with residual ovarian cancer. Clinical and pathological correlations. Gynecol Oncol 7:288–295, 1979.

    PubMed  CAS  Google Scholar 

  28. Van Nagell JR, Donaldson ES, Gay EC, Sharkey RM, Rayburn P, Goldenberg DM: Carcinoembryonic antigens in ovarian epithelial cystadenocarcinomas. The prognostic value of tumor and serial plasma determinations. Cancer 41:2335–2340, 1978.

    PubMed  Google Scholar 

  29. McIntire KR, Waldmann TA: Measurement of alpha fetoprotein. In: Manual of Clinical Immunology. Rose NR, Friedman H (eds). Washington D.C.: American Society for Microbiology, 1980 (2nd ed), pp 936–943.

    Google Scholar 

  30. Van Nagell JR Jr, Donaldson ES, Hanson MB, Gay EC, Pavlik EJ: Biochemical markers in the plasma and tumors of patients with gynecologic malignancies. Cancer 48:495–503, 1981.

    PubMed  Google Scholar 

  31. Malkin A, Kellen JA, Kickrish GM, Bush RS: Carcinoembryonic antigen (CEA) and other tumor markers in ovarian and cervical cancer. Cancer 42:1452–1456, 1978.

    PubMed  CAS  Google Scholar 

  32. Stanhope CR, Smith JP, Britton JC, Crosley PK: Serial determination of marker substances in ovarian cancer. Gynecol Onc 8:284–287, 1979.

    CAS  Google Scholar 

  33. Levi MM, Parshley MS, Mandl I: Antigenicity of papillary serous cystadenocarcinoma tissue culture cells. Am J Obstet Gynecol 102:433–439, 1968.

    PubMed  CAS  Google Scholar 

  34. Levi MM: Antigenicity of ovarian and cervical malignancies with a view toward possible immunodiagnosis. Am J Obstet Gynecol 109:689–698, 1971.

    PubMed  CAS  Google Scholar 

  35. Gall SA, Walling J, Pearl J: Demonstration of tumor-associated antigens in human gynecologic malignancies. Am J Obstet Gynecol 115:387–393, 1973.

    PubMed  CAS  Google Scholar 

  36. Dorsett BH, Ioachim HL: Common antigenic component in ovarian carcinomas: Demonstration by double diffusion and immunofluorescence techniques. Immunol Communic 2:173–184, 1973.

    CAS  Google Scholar 

  37. Ioachim HL, Dorsett BH, Sabbath M, Andersson BS, Barber HRK: Antigenic and morphologic properties of ovarian carcinoma. Gynecol Onc 1:130–142, 1973.

    Google Scholar 

  38. Order SE, Thurston J, Knapp R: Ovarian tumor antigens: A new potential for therapy. Natl Cancer Inst Monogr 42:33–43, 1975.

    PubMed  CAS  Google Scholar 

  39. Imamura N, Takahashi T, Lloyd KO, Lewis JL, Old LJ: Analysis of human ovarian tumor antigens using heterologous antisera: detection of new antigenic systems. Int J Cancer 21:570–577, 1978.

    PubMed  CAS  Google Scholar 

  40. Lloyd KO: Ovarian cancer antigen OVC-2. In: Compendium of Assay for Immunodiagnosis of Human Cancer. Herberman RB (ed). Amsterdam: Elsevier, North Holland Inc, 1978, p 533.

    Google Scholar 

  41. Klein JL, Gall SA, Dawson JR: Quantitation of secretory component levels in cyst fluids, ascitic fluids and sera from ovarian adenocarcinoma patients. J Natl Cancer Inst 61:57–60, 1978.

    PubMed  CAS  Google Scholar 

  42. Burton RM, McGrew TL, Barrows GH, Beyerle MP, Fortwengler HP, Day TG, Kuhns JG, Espinosa E: Occurrence of a thermostable antigen of ovarian carcinoma in normal tissues and secretions. Cancer 43:2385–2391, 1979.

    PubMed  CAS  Google Scholar 

  43. Bara J, Malarewics A, Loisillier F, Burtin P: Antigens common to human ovarian mucinous cyst fluid and gastric mucosa. Br J Cancer 36:49–56, 1977.

    PubMed  CAS  Google Scholar 

  44. Axelsen NH: WHO-Collaborative study on ovarian tumor associated antigens. 1979.

    Google Scholar 

  45. Cantarow WD, Stolbach LL, Bhattacharya M, Chatterjee SK, Barlow JJ: The value of tumor markers in cancer of the ovary. Int J Rad Oncol Biol Phys, in press.

    Google Scholar 

  46. Bhattacharya M, Barlow JJ: Ovarian tumor antigens. Cancer 42:1616–1620, 1978.

    PubMed  CAS  Google Scholar 

  47. Bhattacharya M, Barlow JJ: Ovarian cystadenocarcinoma-associated antigen (OCAA). In: Compendium of Assays for Immunodiagnosis of Human Cancer. Herberman RB (ed). Amsterdam: Elsevier, North Holland Inc, 1979, pp 527–431.

    Google Scholar 

  48. Knauf S, Urbach GI: Purification of human ovarian tumor-associated antigen and demonstration of circulating tumor antigen in patients with advanced ovarian malignancy. Am J Obstet Gynecol 127:705–711, 1977.

    PubMed  CAS  Google Scholar 

  49. Knauf S, Urbach GI: The development of a durable antibody radioimmunoassay for detecting ovarian tumor-associated antigen fraction OCA in plasma. Am J Obstet Gynecol 131:780–787, 1978.

    PubMed  CAS  Google Scholar 

  50. Knauf S, Urbach GI: OCA, ovarian tumor associated antigen. In: Compendium of Assays for Immunodiagnosis of Human Cancer. Herberman RB (ed). Amsterdam: Elsevier, North Holland Inc, 1979, pp 537–539.

    Google Scholar 

  51. Knauf S, Urbach GI: A study of ovarian cancer patients using a radioimmunoassay for human ovarian tumor associated antigen OCA. Am J Obstet Gynecol 138:1222–1223, 1980.

    PubMed  CAS  Google Scholar 

  52. Knauf S, Urbach GI: Identification, purification and radioimmunoassay of NB/70K, a human ovarian tumor-associated antigen. Cancer Res 41:1351–1357, 1981.

    PubMed  CAS  Google Scholar 

  53. Hollinshead A: Skin test to identify TAA and TAA hyperimmune antisera for use in ELISA. In: Compendium of Assays for Immunodiagnosis of Human Cancer. Herberman RB (ed). Amsterdam: Elsevier, North Holland Inc, 1979, pp 543–551.

    Google Scholar 

  54. Dorsett BH, Ioachim HL, Stohlbach L, Walker J, Barber HRK: Isolation of tumor-specific antibodies from effusions of ovarian carcinomas. Int J Cancer 16:779–786, 1975.

    PubMed  CAS  Google Scholar 

  55. Dorsett BH, Ioachim HL: Ovarian tumor related factors in peritoneal effusions. In: Compendium of Assays for Immunodiagnosis of Human Cancer, Herberman RB (ed). Amsterdam: Elsevier, North Holland Inc, 1979, pp 559–561.

    Google Scholar 

  56. Stolbach LL, Cantarow WD, Gronin WJ, Dorsett B, Ghandbir L, Hamm J, Ioachim H, Kelloway K, McLaughlin M, Walker J, Barber HRK: Dissociation and characterization of ovarian cancer antigen (Ag) and antibody (Aby) from immune complexes. Proc Amer Assoc Cancer Res 21:239, 1980.

    Google Scholar 

  57. Cantarow WD, Gronin WJ, Dorsett B, Gandbhir L, Hamm J, Ioachim H, Kelloway K, McLaughlin M, Walker J, Stolbach L, Barber HRK: Characterization of ovarian cancer antigen and antibody from immune complexes. Fed Proc 39:474, 1980.

    Google Scholar 

  58. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497, 1975.

    PubMed  CAS  Google Scholar 

  59. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337, 1981.

    PubMed  Google Scholar 

  60. Sang D, Bast RC Jr, Lazarus H, Terhorst C, Knapp RC: Unpublished data.

    Google Scholar 

  61. Kabawat S, Bast RC Jr, Colvin RB, Welch W, Knapp RC: Unpublished data.

    Google Scholar 

  62. Van Nagell JR Jr, Kim E, Casper S, Primus FS, Bennett S, Deland FH, Goldenberg DM: Radioimmunodetection of primary and metastatic ovarian cancer using radiolabeled antibodies to carcinoembryonic antigen. Cancer Res 40:502–506, 1980.

    PubMed  Google Scholar 

  63. Mandell GL, Fisher RI, Bostick F, Young RC: Ovarian Cancer: A solid tumor with evidence of normal cellular immune function but abnormal B cell function. Am J Med 66:621–624, 1979.

    PubMed  CAS  Google Scholar 

  64. Kohorn EI, Mitchell MS, Dwyer JM, Knowlton AH, Klein-Angerer S: Effect of radiation on cell-mediated cytotoxicity and lymphocyte subpopulations in patients with ovarian carcinoma. Cancer 41:1040–1048, 1978.

    PubMed  CAS  Google Scholar 

  65. Halili M, Bosworth J, Romney S, Moukhtar M, Ghossein A: The long term effect of radiotherapy on the immune status of patients cured of a gynecologic malignancy. Cancer 37:2875–2878, 1976.

    PubMed  CAS  Google Scholar 

  66. Nalick RH, DiSaia PJ, Rea TH, Morrow CP: Immunocompetence and prognosis in patients with gynecologic cancer. Gynecol Oncol 2:81–92, 1974.

    PubMed  CAS  Google Scholar 

  67. Check IJ, Hunter RC, Rosenberg KD, Herbst AL: Prediction of survival in gynecological cancer based on immunological tests. Cancer Res 40:4612–4616, 1980.

    PubMed  CAS  Google Scholar 

  68. Mantovani A, Allvena P, Sessa C, Bolis G, Mangioni C: Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors. Int J Cancer 25:573–582, 1980.

    PubMed  CAS  Google Scholar 

  69. Allavona P, Introna M, Mangioni C, Mantovani A: Inhibition of natural killer activity by tumor associated lymphoid cells from ascites ovarian carcinomas. J Natl Cancer Institute 67:319–325, 1981.

    Google Scholar 

  70. Svanberg L, Astadt B: Coagulative and fibrinolytic properties of ascites fluid associated with ovarian tumors. Cancer 35:1382–1387, 1975.

    PubMed  CAS  Google Scholar 

  71. Veda K, Toyokawa M, Nakamori H, Sako H, Umesaki N, Nakade J, Lee T, Sugawa T: The prognostic value of serum immunosuppressive effect in patients with ovarian cancer. Obstet Gynecol 53:480–483, 1979.

    Google Scholar 

  72. Hess AD, Gall SA, Dawson JR: Inhibition of in vitro lymphocyte function by cyst and ascitic fluids from ovarian cancer patients. Cancer Res 39:2381–2389, 1979.

    PubMed  CAS  Google Scholar 

  73. Hess AD, Gall SA, Dawson JR: Partial purification and characterization of lymphocyte-inhibitory factor(s) in ascitic fluid from ovarian cancer patients. Cancer Res 40:1842–1851, 1980.

    PubMed  CAS  Google Scholar 

  74. Hess AD, Gall SA, Dawson JR: Inhibition of human lymphoblastoid cell line proliferation by ascites fluid from ovarian cancer patients. Cancer Res 40:4455–4500, 1980.

    Google Scholar 

  75. Badger AM, Cooperband SR: An immunostimulatory substance in the ascites fluid of patients with cancer metastatic to the peritoneum. Cell Immunol 45:15–25, 1979.

    PubMed  CAS  Google Scholar 

  76. Badger AM, Oh SK, Moulten RF: Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody-dependent cytotoxicity. Cancer Res 41:1133–1139, 1981.

    PubMed  CAS  Google Scholar 

  77. Tamura K, Shibate Y, Matsuda Y, Ishida N: Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 41: 3244–3252, 1981.

    PubMed  CAS  Google Scholar 

  78. Robinson E, Sher S, Mekori T: Lymphocyte stimulation by phytohemagglutinin and tumor cells of malignant effusions. Cancer Res 36:1548–1551, 1974.

    Google Scholar 

  79. Salmon SE, Hamberger AW: Immunoproliferation and cancer: A common macrophage derived promoter substance. Lancet 1:1289–1290, 1978.

    PubMed  CAS  Google Scholar 

  80. Hamberger AW, Salmon SE, Kim MB, Trent JM, Soehnlen BY, Alberts DS, Schmidt HJ: Direct cloning of human ovarian cancer cell in agar. Cancer Res 38:3438–3444, 1978.

    Google Scholar 

  81. Hamberger AW, Salmon SE, Alberts DS: Development of a bioassay for ovarian carcinoma colony forming cells. In: Cloning of Human Tumor Stem Cells. Salmon SE (ed). New York: Alan R Liss, 1980, pp 63–73.

    Google Scholar 

  82. Buick RN, Fry SE, Samon SE: Effect of host-cell interactions on clonogenic carcinoma cells in human malignant effusions. Br J Cancer 41:695–704, 1980.

    PubMed  CAS  Google Scholar 

  83. Buick RN, Salmon SE: Variables in the demonstration of human tumor clonogenicity: Cell interactions and semi-solid support. In: Cloning of Human Tumor Cells. Salmon SE (ed). New York: Alan R Liss, 1980, pp 127–134.

    Google Scholar 

  84. Mantovani A, Polentarutti N, Peri G, Shavit ZB, Vecchi A, Bollis G, Mangioni C: Cytotoxicity of tumor cells of peripheral blood monocytes and tumor associated macrophages in patients with ascites ovarian tumors. JNCI 64:1307–1315, 1980.

    PubMed  CAS  Google Scholar 

  85. Mantovani A, Peri G, Polentarutti N, Bolis G, Mangioni C, Spreafico F: Effects of in vitro tumor growth of macrophages isolated from human ascitic ovarian tumors. Int J Cancer 23:157–164, 1979.

    PubMed  CAS  Google Scholar 

  86. Chatterjee J, Barlow JJ, Allen HJ, Chung WS, Piver S: Lymphocyte response to autologous tumor antigen(s) and phytohemagglutinins in ovarian cancer patients. Cancer 3:956–962, 1975.

    Google Scholar 

  87. Chen SY, Koffler D, Cohen CJ: Cell mediated immunity in patients with ovarian carcinoma. Am J Obstet Gynecol 115:467–470, 1973.

    PubMed  CAS  Google Scholar 

  88. Feiferman I, Gleicher N, Cohen CJ, Koffler D: Leukocyte migration in ovarian carcinoma: Comparison of inhibitory activity of tumor extracts. JNCI 59:1593–1597, 1977.

    Google Scholar 

  89. Melnick H, Barber HRK: Cellular immunologic responsiveness to extracts of ovarian epithelial tumors. Gynecol Onc 3:77–86, 1975.

    CAS  Google Scholar 

  90. Gleicher N, Beers P, Cohen CJ, Kerengi TD, Gusberg S: Leukocyte migration enhancement as an indicator of immunologic enhancement. Am J Obstet Gynecol 136–124, 1980.

    Google Scholar 

  91. Gleicher N, Beers P, Cohen CJ, Kerengi TD, Gusberg SB: Leukocyte migration enhancement as an indicator of immunologic enhancement. III. Common denominators of pregnancy and malignancy. Am J Obstet Gynecol 136:5–10, 1980.

    PubMed  CAS  Google Scholar 

  92. DiSaia PJ, Rutledge FN, Smith JP, Sinkovics: Cell mediated immune reaction to two gynecologic malignant tumors. Cancer 28:1129–1137, 1971.

    Google Scholar 

  93. DiSaia PJ, Sinkovics JG, Rutledge FN, Smith JP: Cell mediated immunity to human malignant cells. Am J Obstet Gynecol 114:979–989, 1972.

    PubMed  CAS  Google Scholar 

  94. DiSaia PJ: Immunological aspects of gynecological malignancies. J Reproductive Med 14:17–20, 1975.

    CAS  Google Scholar 

  95. Patillo RA, Story MT, Ruckert CF: Expression of cell-mediated immunity and blocking factor using a new line of ovarian cancer cells in vitro. Cancer Res 39:1185–1191, 1979.

    Google Scholar 

  96. Patillo RA, Ruckert ACF, Story MT, Mattingly RF: Immunodiagnosis in ovarian cancer: Blocking factor activity. Am J Obstet Gynecol 133:791, 1979.

    Google Scholar 

  97. DiSaia PJ, Nalick RH, Townsend DE: Antibody cytotoxicity studies in ovarian and cervical malignancies. Ob Gyn 42:644–650, 1973.

    CAS  Google Scholar 

  98. Garcia JA, Klein JL, Kotteh WH, Dawson JR, Gall SA: Immunologic studies on the cystic effusions of ovarian epithelial neoplasms. Am J Obstet Gynecol 129:281–284, 1977.

    PubMed  CAS  Google Scholar 

  99. Halbrecht I, Komlos L: Cytotoxic effects of various sera on primary cultures of placentas and ovarian tumors. Obstet Gynecol 38:594–598, 1971.

    PubMed  CAS  Google Scholar 

  100. Poulton TA, Crowther ME, Hay FC, Nineham LJ: Immune complexes in ovarian cancer. Lancet ii: 72–73, 1978.

    Google Scholar 

  101. McLaughlin PJ, Price MR, Baldwin RW, Vasey D, Symonds EM: Immune complexes in ovarian cancer. Lancet ii:271, 1978.

    Google Scholar 

  102. Clayton LA, Gall SA, Dawson JR, Creasman WT: Immune complexes in ovarian cancer. Proc Soc Gyn Oncol 12:21–22, 1981.

    Google Scholar 

  103. Nauts HC: Beneficial effects of acute concurrent infection, inflammation, fever on immunotherapy (bacterial toxins) in ovarian and uterine cancer. Cancer Research Institute Monograph 17:1–122, 1977.

    Google Scholar 

  104. Graham JB, Graham RM: The effect of vaccine on cancer patients. Surg Gyn Obstet 109: 131–138, 1959.

    CAS  Google Scholar 

  105. Graham JB, Graham RM: Autogenous vaccine in cancer patients. Surg Gyn Obstet 114: 1–4, 1962.

    CAS  Google Scholar 

  106. Sonkin R, Coudagras M, Blondon J: Traitement des cancers génitaux par la polycimoitherapie. Multiple sequential chemotherapy in patients with advanced gynecological cancer. (Fr) J Gyn Obst Biol Repr 1:61–69, 1972.

    CAS  Google Scholar 

  107. Hudson CN, Levin L, McHardy JE, Poulton TA, Curling OM, Crowther M, English PE, Leighton M: Active specific immunotherapy for ovarian cancer. Lancet 2:877–879, 1976.

    PubMed  CAS  Google Scholar 

  108. Alberts DS: Adjuvant Immunotherapy with BCG of Advanced Ovarian Cancer: A preliminary report. Salmon SE, Jones SE (eds). Amsterdam: Elsevier, North Holland, Bio-medical Press, 1977, pp 327–337.

    Google Scholar 

  109. Mangan C, Jeqlum KA, Sedlacek TV, Giuntoli RC, Wheeler JE, Rubin E, Mikuta JJ: Intralymphatic BCG in the treatment of gynecologic malignancies: A Phase I Study. Cancer 40:2933–2940, 1977.

    PubMed  CAS  Google Scholar 

  110. Papaioannou AW, Polychronis AB, Agoustis AW, Coco HI, Trichopoulas DB: Maximal cytoreduction, chemotherapy and contact nonspecific immunotherapy for Stage III ovarian cancer.

    Google Scholar 

  111. Brandes LJ: Immunotherapy for ovarian cancer. Lancet 2:1195, 1976.

    PubMed  CAS  Google Scholar 

  112. Alberts DS, Mason NL, O’Toole R, Nef TJ, Hilgers R, Carlin D, Moon TE: A randomized trial doxorubicin and cyclophosphamide plus BCG versus doxorubicin and cyclophos-phamide therapy in advanced ovarian cancer. Immunotherapy of Human Cancer. Terry WD, Rosenberg S (eds). New York: Excerpta Medica, 1982, pp 343–352.

    Google Scholar 

  113. Chang VST, Suit HD, Wang CC, Raker J, Weymuller E, Kaitman S: A preliminary study of intralesional, intralymph node, intravenous and intraperitoneal Corynebacterium parvum treatments in patients with advanced cancer. Cancer 42:1912–1915, 1978.

    Google Scholar 

  114. Webb HE, Oaten SE, Pike CP: Treatment of malignant ascitic and pleural effusions with Corynebacterium parvum. Brit Med J 1:338–340, 1978.

    PubMed  CAS  Google Scholar 

  115. Bast RC Jr, Berek JS, Obrist R, Griffiths CT, Berkowitz R, Hacker NF, Parker L, Lagasse LD, Knapp RC: Intraperitonal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Proc Amer Soc Clin Oncol 1:38, 1982.

    Google Scholar 

  116. Mantovani A, Sessa C. Peri G, Allvena P, Introna M, Polentarutti N, Mangioni C: Intraperitoneal administration of Corynebacterium parvum in patients with ascitic ovarian tumors resistant to chemotherapy: Effects on cytotoxicity of tumor associated macrophages and NK cells. Int J Cancer 27:437–446, 1981.

    PubMed  CAS  Google Scholar 

  117. DiSaia PJ, Rich WM: Value of immune monitoring in gynecologic cancer patients receiving immunotherapy. Am J Obstet Gynecol 135:907–916, 1979.

    PubMed  CAS  Google Scholar 

  118. Gall SA, DiSaia PJ, Schmidt H, Mittelstaed L, Newman P, Creasman W: Toxicity manifestations following intravenous Corynebacterium parvum administration to patients with ovarian and cervical carcinoma. Am J Obstet Gynecol 132:555–560, 1978.

    PubMed  CAS  Google Scholar 

  119. Rao B, Wanebo HJ, Ochoa M, Lewis JL, Oettgen HF: Intravenous C. parvum. An adjuvant to chemotherapy for resistent advanced ovarian cancer. Cancer 39:514–526, 1977.

    PubMed  CAS  Google Scholar 

  120. Gall SA, Creasman WT, Blessing JA, Whisnant JK, DiSaia PJ: Chemoimmunotherapy in primary stage III ovarian epithelial cancer. Immunotherapy of Human Cancer. Terry WD, Rosenberg S (eds). New York: Excerpta Medica, 1982, pp 337–342.

    Google Scholar 

  121. Bast RC Jr, Berek JS, Obrist R, Griffiths CT, Berkowitz R, Hacker NF, Parker L, Lagasse LD, Knapp RC: Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res, in press.

    Google Scholar 

  122. Wanebo HJ, Ochoa M Jr, Gunther U, Ishi T, Lewis JF Jr, Oettgen HF: Randomized chemoimmunotherapy trial of CAF and intravenous C parvum for resistant ovarian carcinoma. Preliminary results. Proc Amer Assoc Cancer Res 18:225, 1977.

    Google Scholar 

  123. Stewart WE, II (ed): Interferons and their Actions. Cleveland, Ohio: CRC Press, 1977.

    Google Scholar 

  124. Epstein LB, Shen J-T, Abele JS, Reese CC: Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semi-solid agar technique. Ann NY Acad Sci 350:228–244, 1980.

    PubMed  CAS  Google Scholar 

  125. Epstein LB, Shen J-T, Abele JS, Reese CC: Further experience in testing the sensitivity of human ovarian carcinoma cells to interferon in an in vitro semi-solid agar culture system: Comparison of solid and ascitic forms of tumor. In: Cloning of Human Tumor Stem Cell. Salmon SE (ed). New York: Alan R Liss, Inc, 1980, pp 277–290.

    Google Scholar 

  126. The Biology of the Interferon System. Amsterdam: Elsevier, Biomedical, Press 1981.

    Google Scholar 

  127. Order S, Rosenshein NB, Klein JL, Lichter AS, Ettinger DS, Dillon MB, Leibel SA: New methods applied to the analysis and treatment of ovarian cancer. Int J Rad Oncol Biol Phys 5:861–873, 1979.

    CAS  Google Scholar 

  128. Order SE, Rosenshein N, Klein JL, Leibel S, Torres JPY, Ettinger D: The integration of new therapies and radiation in management of ovarian cancer. Cancer 48:590–596, 1981.

    PubMed  CAS  Google Scholar 

  129. Fekete E, Ferrigno MA: Studies on a transplantable teratoma of the mouse. Cancer Res 12:438–440, 1952.

    PubMed  CAS  Google Scholar 

  130. Verhaelen CPJ, Fisher RI, Apella E, Ramanathan L: Lack of histocompatibility antigens on a murine ovarian teratocarcinoma. Cancer Res 41:3186–3191, 1981.

    Google Scholar 

  131. Feldman GB, Knapp RC, Order SE, Hellman S: The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 32:1663–1666, 1972.

    PubMed  CAS  Google Scholar 

  132. Feldman GB: Lymphatic obstruction in carcinomatous ascites. Cancer Res 35:325–332, 1975.

    PubMed  CAS  Google Scholar 

  133. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC: Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39:3209–3214, 1979.

    PubMed  CAS  Google Scholar 

  134. Ozols RF, Grotzinger KR, Fisher RI, Myers CE, Young RC: Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer. Cancer Res 39: 3202–3208, 1979.

    PubMed  CAS  Google Scholar 

  135. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Fisher RI, Young RC: Chemotherapy for murine ovarian cancer: A rational for IP therapy with adriamycin. Cancer Treat Rep 63:269–273, 1979.

    PubMed  CAS  Google Scholar 

  136. Finkler N, Cohen CJ: A study of distribution patterns and improved therapeutic techniques in the treatment of ovarian neoplasms with cis-diamminedichloroplatinum. Proc Soc Gyn Onc 12:30–35, 1981.

    Google Scholar 

  137. Verhaelen CPJ, Fisher RI: Requirements for successful immunotherapy and chemoimmu-notherapy of a murine model of ovarian cancer. Cancer Res 41:980–983, 1981.

    Google Scholar 

  138. Order SE, Donahue V, Knapp R: Serologic immunotherapy and interaction with radiation. In: Interaction of Radiation and Host Immune Defense Mechanisms, in Malignancy. Bond VP (ed). Brookhaven National Laboratory (Publ 50418), 1974, pp 363–372.

    Google Scholar 

  139. Bloomer WD, Adelstein SJ: 5-125I-iododeoxyuridine as prototype for radionuclide therapy with Arger emittors. Nature 265:620–621, 1977.

    PubMed  CAS  Google Scholar 

  140. Bloomer WD, McLaughlin WH, Neirinckx RD, Adelstein SJ, Gordon PR, Ruth TJ, Wolf AP: Astatine-211-tellurium radiocolloid cures experimental malignant ascites. Science 212:340–341, 1981.

    PubMed  CAS  Google Scholar 

  141. Reif AE: An experimental test of two general relationships to describe the absorption of antibodies by cells and tissues. Immunochem 3:267–278, 1966.

    CAS  Google Scholar 

  142. Order SE, Donahue V, Knapp R: Immunotherapy of ovarian carcinoma: An experimental model. Cancer 32:573–579, 1973.

    PubMed  CAS  Google Scholar 

  143. Michaelson J, Artzt K, Bennett D, Caldwell J, Heath JK: A cell surface antigen, TER, expressed by embryos and germ cells. J Immunol 123:2436–2438, 1979.

    PubMed  CAS  Google Scholar 

  144. Order SE, Kirkman R, Knapp R: Serologic immunotherapy: Results and probable mechanism of action. Cancer 34:175–183, 1974.

    PubMed  CAS  Google Scholar 

  145. Bast RC Jr, Knapp RC, Donahue VC, Thurston JG, Mitchell AR, Feeney M, Schlossman SF: Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. J Natl Cancer Inst 64:365–372, 1980.

    PubMed  Google Scholar 

  146. Order SE, Donahue V, Knapp R: Serologic immunotherapy and interaction with radiation. In: Interaction of Radiation and Host Immune Defense Mechanisms in Malignancy. Bond VP (ed). Brookhaven National Laboratory (Publ 50418), 1974, pp 363–372.

    Google Scholar 

  147. Knapp RC, Berkowitz RS: Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model. Am J Obstet Gynecol 128:782–786, 1977.

    PubMed  CAS  Google Scholar 

  148. Bast RC Jr, Knapp RC, Mitchell AK, Thurston JG, Tucker REV, Schlossman SF: Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. 1. Activation of peritoneal cells to mediate antibody dependent cytotoxicity. J Immunol 123:1945–1951, 1979.

    PubMed  Google Scholar 

  149. Burstein S, Knapp RC: Chemotherapy of murine ovarian carcinoma by methotrexate-antibody conjugates. J Med Chem 20:950–952, 1977.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Robert C. Bast Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert C. Knapp
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, USA

    C. Thomas Griffiths M.D.

  2. Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

    Arlan F. Fuller Jr. M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Bast, R.C., Knapp, R.C. (1983). The Immunobiology of Ovarian Carcinoma. In: Griffiths, C.T., Fuller, A.F. (eds) Gynecologic Oncology. Cancer Treatment and Research, vol 10. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3852-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3852-9_6

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3854-3

  • Online ISBN: 978-1-4613-3852-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation